Matinas BioPharma
enact cohort results validation of efficacy and safety | Matinas BioPharma
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
9 of 28
Similar slides by Matinas BioPharma
See diffirences between slides (animation)
Investor Presentation
March 2024
enact phase clinical validation of safety and efficacy | Matinas BioPharma
Investor Presentation
February 2024
enact phase clinical validation of safety and efficacy a | Matinas BioPharma
Investor Presentation
January 2024
enact phase clinical validation of safety and efficacy | Matinas BioPharma
Investor Presentation
November 2023
enact phase clinical validation of safety and efficacy | Matinas BioPharma
Related slides by other companies
argenx SE
Results
June 2023
for multifocal motor neuropathy advancing phase study to cohort a | argenx SE
MAIA Biotechnology
Investor Presentation
July 2023
thio trial patients dosed to date | MAIA Biotechnology
Ocuphire Pharma
Results
October 2022
has the potential to be first line of therapy for patients efficacy signal safety non invasive treatment option guidance physician patients efficacy signal safety non invasive treatment option | Ocuphire Pharma
DICE Therapeutics
Investor Presentation
March 2023
define the optimal inhibitory profile | DICE Therapeutics
Other recent decks by Matinas BioPharma
See all presentations (7 decks)
Investor Presentation
March 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights